Medicament for treating lung cancer

Details Medicament for treating lung cancer Medicament for treating lung cancer

2006-08-15

2006-08-15

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S027000, C514S033000, C514S049000, C514S283000

Reexamination Certificate

active

07091189

ABSTRACT:
By using a combination of amrubicin or a pharmaceutically acceptable salt thereof with another medicament for treating lung cancer (irinotecan, vinorelbine, gemcitabine, etc.), it is intended to provide medicaments for treating lung cancer having an improved antitumor therapeutic effect on lung cancer and reduced side effects. Lung cancer can be effectively treated using these medicaments.

REFERENCES:
patent: 6544962 (2003-04-01), Jones et al.
patent: 6747055 (2004-06-01), Ho et al.
patent: 2003/0157097 (2003-08-01), Noguchi et al.
patent: 2004/0038913 (2004-02-01), Noguchi et al.
patent: WO-02/09754 (2002-02-01), None
patent: WO-02/060453 (2002-08-01), None
Sumitomo, “Amrubicin Hydrochloride”, Drugs of the Future, vol. 22, pp. 1271-1272, 1997.
Hida et al., Clinical Cancer Research, vol. 6, pp. 2006-2011, 2000.
Yanagi et al., Japanese Cancer Association, abstract No. 2168, 1989.
Yamauchi et al., “Combination effects of Amrubicin, a Novel Anthracycline, With Cisplatin on Human Lung Cancer Cells”, European Journal of Cancer, vol. 37, suppl. 6, pp. 159, 2001.
Ettinger, David S., “New Drugs for Chemotherapy-Naive Patients with Extensive-Disease Small Cell Lung Cancer”, Seminars in Oncology, (2001), vol. 28, No. 2, Suppl. 4, pp. 27 to 29.
Turrisi, A.T., et al., “The Treatment of Limited Small Cell Lung Cancer: A Report of the Progress Made and Future Prospects”, European Journal of Cancer, (2002), vol. 38, Issue 2, pp. 279 to 291.
Fukuoka, M., “Current Perspectives of New Agents in Lung Cancer”, Nippon Rinsho (Japanese Journal of Clinical Medicine), (2000), vol. 58, No. 5, pp. 1103 to 1110.
Masuda, N., “Small-Cell Lung Cancer”, Nippon Rinsho (Japanese Journal of Clinical Medicine), (2000), vol. 58, No. 5, pp. 1121 to 1126.
Yamauchi, S., et al., “Combination Effects of Amrubicin, A Novel Anthracycline, with Cisplatin on Human Lung Cancer Cells”, European Journal of Cancer, (2001), vol. 37, Suppl. 6, p. S46, 159.
Takagi et al., Investigational New Drugs, vol. 14, pp. 357-363, (1996).
Hida et al., Clinical Cancer Research, vol. 6, pp. 2006-2011, (2000).
Ohe et al., Cancer Research, vol. 49, pp. 4098-4102, (Aug. 1, 1989).
Yanagi et al., Abstract of publication in Japanese Cancer Association No. 2168, (1989).
“Amrubicin Hydrocholoride” Drugs of the Future, vol. 22, pp. 1271-1272, (1997), XP009034298.
Takigawa et al., Acta Med Okayama, vol. 46, pp. 249-256, (1992), XP009034562.
Vogl et al., Cancer, vol. 38, pp. 21-26, (1976).

Affiliated with

Also associated with

Rating

Medicament for treating lung cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medicament for treating lung cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicament for treating lung cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3657358